PKO Investment Management Joint Stock Co Decreases Stock Holdings in Axon Enterprise, Inc $AXON

PKO Investment Management Joint Stock Co reduced its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 31.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,000 shares of the biotechnology company’s stock after selling 1,400 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Axon Enterprise were worth $1,274,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Legal & General Group Plc boosted its position in shares of Axon Enterprise by 1.3% during the 4th quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after acquiring an additional 5,419 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in Axon Enterprise during the fourth quarter worth about $13,116,000. Wealth Enhancement Advisory Services LLC increased its position in Axon Enterprise by 93.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock worth $13,270,000 after purchasing an additional 11,262 shares during the last quarter. Teamwork Financial Advisors LLC raised its stake in Axon Enterprise by 40.5% during the fourth quarter. Teamwork Financial Advisors LLC now owns 25,352 shares of the biotechnology company’s stock worth $14,398,000 after purchasing an additional 7,307 shares during the period. Finally, Clearbridge Investments LLC raised its stake in Axon Enterprise by 21.1% during the fourth quarter. Clearbridge Investments LLC now owns 343,910 shares of the biotechnology company’s stock worth $195,317,000 after purchasing an additional 59,821 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a research note on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating and issued a $674.00 price objective on shares of Axon Enterprise in a research report on Monday, June 15th. Citizens Jmp cut their target price on Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a research note on Thursday, May 7th. Royal Bank Of Canada reduced their target price on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. upped their price target on Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $712.75.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $410.03 on Tuesday. The company’s 50 day simple moving average is $414.43 and its 200-day simple moving average is $484.39. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The company has a market capitalization of $33.05 billion, a price-to-earnings ratio of 164.67, a price-to-earnings-growth ratio of 7.70 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.90 million. During the same quarter last year, the company posted $1.47 EPS. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. As a group, equities research analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Insider Activity at Axon Enterprise

In other news, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total value of $800,000.00. Following the completion of the sale, the insider directly owned 52,813 shares of the company’s stock, valued at approximately $21,125,200. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Joshua Isner sold 13,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares in the company, valued at $82,609,106.25. This represents a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,989 shares of company stock valued at $19,090,083 over the last ninety days. 4.20% of the stock is owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.